Merrion Pharmaceuticals plc Announces Commencement of Next Stage of Oral Drug Research Collaboration Programme With Novo Nordisk
Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on from the completion of several oral feasibility studies combining Merrion's Gastrointestinal permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation of this collaboration, Merrion will now complete the development of solid dosage forms with GIPET for additional testing.
"We are very pleased to be working on oral versions of Novo Nordisk's compounds. We believe there can be substantial benefit to patients in having oral formulations on these compounds available -- and our GIPET technology has shown the ability to significantly improve the oral delivery of these drugs," John Lynch, Merrion's CEO said.
In more than 20 clinical studies, GIPET technology has been shown to improve the oral absorption of a wide range of drugs, by between 500% and 1500%. Drugs studied ranged from small molecules to small proteins. Merrion currently has four products in development, as well as several collaboration agreements with pharmaceutical partners, using this technology.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
